Clinical Trial Update: Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Peginterferon Lambda for 48 weeks in patients with Hepatitis Delta Virus is underway (status unknown).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis Delta Virus

Drugs mentioned

• Peginterferon lambda (peginterferon lambda)

Snippet

Sponsor: Eiger BioPharmaceuticals | Conditions: Hepatitis Delta Virus | Phase 3 | Status: UNKNOWN